AUGX - Augmedix, Inc. Stock Price, Fair Value and News

2.74USD+0.04 (+1.48%)Delayed as of 07 May 2024, 10:52 am ET

Market Summary

USD2.74+0.04

Delayedas of 07 May 2024, 10:52 am

1.48%

AUGX Alerts

1 major insider sales recently.

AUGX Stock Price

View Fullscreen

AUGX RSI Chart

AUGX Valuation

Market Cap

132.2M

Price/Earnings (Trailing)

-6.9

Price/Sales (Trailing)

2.95

EV/EBITDA

-5.24

Price/Free Cashflow

-7.13

AUGX Price/Sales (Trailing)

AUGX Profitability

Operating Margin

51.85%

EBT Margin

-42.42%

Return on Equity

-82.2%

Return on Assets

-28.74%

Free Cashflow Yield

-14.03%

AUGX Fundamentals

AUGX Revenue

Revenue (TTM)

44.9M

Rev. Growth (Yr)

44.9%

Rev. Growth (Qtr)

7.76%

AUGX Earnings

Earnings (TTM)

-19.2M

Earnings Growth (Yr)

19.77%

Earnings Growth (Qtr)

-1.93%

Breaking Down AUGX Revenue

52 Week Range

2.695.75

(Low)(High)

Last 7 days

-4.6%

Last 30 days

-33%

Last 90 days

-38.6%

Trailing 12 Months

-27.0%

How does AUGX drawdown profile look like?

AUGX Financial Health

Current Ratio

2.41

AUGX Investor Care

Shares Dilution (1Y)

20.39%

Diluted EPS (TTM)

-0.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	33.6M	37.0M	40.9M	44.9M
2022	24.4M	26.5M	28.8M	30.9M
2021	17.3M	18.8M	20.1M	22.2M
2020	14.7M	15.3M	15.9M	16.5M
2019	0	0	0	14.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Augmedix, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	shakil ian	acquired	430	0.86	500	chief strategy officer
Apr 15, 2024	shakil ian	sold	-1,900	3.8	-500	chief strategy officer
Apr 12, 2024	shakil ian	sold	-74,589	3.8165	-19,544	chief strategy officer
Apr 12, 2024	shakil ian	acquired	16,807	0.86	19,544	chief strategy officer
Apr 11, 2024	shakil ian	sold	-97,476	3.934	-24,778	chief strategy officer
Apr 11, 2024	shakil ian	acquired	21,309	0.86	24,778	chief strategy officer
Apr 10, 2024	shakil ian	acquired	31,361	0.86	36,467	chief strategy officer
Apr 10, 2024	shakil ian	sold	-141,288	3.8744	-36,467	chief strategy officer
Apr 09, 2024	shakil ian	sold	-130,521	4.138	-31,542	chief strategy officer
Apr 09, 2024	shakil ian	acquired	23,967	0.759869	31,542	chief strategy officer

Which funds bought or sold AUGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 03, 2024	Householder Group Estate & Retirement Specialist, LLC	unchanged	-	-2,456	6,544	-%
May 03, 2024	ESSEX INVESTMENT MANAGEMENT CO LLC	added	31.09	-197,090	2,163,550	0.43%
May 02, 2024	THOMPSON DAVIS & CO., INC.	sold off	-100	-119,925	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	NORDEN GROUP LLC	sold off	-100	-74,593	-	-%
Apr 29, 2024	HighMark Wealth Management LLC	unchanged	-	-10,560	24,540	0.01%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	319,000	319,000	-%
Apr 25, 2024	nVerses Capital, LLC	new	-	47,444	47,444	0.11%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-101,141	-	-%
Apr 19, 2024	Taylor Frigon Capital Management LLC	sold off	-100	-259,155	-	-%

Are Funds Buying or Selling AUGX?

Are funds buying AUGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AUGX

No. of Funds

AUGX Alerts

1 major insider sales recently.

Unveiling Augmedix, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 26, 2024	dcm vi, l.p.	0.6%	269,490	SC 13D/A
Feb 09, 2024	samjo management, llc	6.1%	2,957,000	SC 13G
Jan 30, 2024	dcm vi, l.p.	6.8%	3,328,014	SC 13D/A
Jan 11, 2024	dcm vi, l.p.	7.9%	3,835,278	SC 13D/A
Dec 29, 2023	dcm vi, l.p.	9.1%	4,438,408	SC 13D/A
Nov 22, 2023	redmile group, llc	40.7%	22,092,211	SC 13D/A
Nov 03, 2023	dcm vi, l.p.	10.9%	0	SC 13D/A
Jun 15, 2023	redmile group, llc	44.7%	20,246,320	SC 13D/A
May 04, 2023	redmile group, llc	44.7%	20,246,320	SC 13D/A
Apr 21, 2023	redmile group, llc	44.7%	20,246,320	SC 13D/A

Recent SEC filings of Augmedix, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 15, 2024	8-K	Current Report
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4/A	Insider Trading
Apr 08, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Augmedix, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	455.8B	371.6B	8.48%	0.02%	20.36	1.23	14.64%	11.24%
CI	97.3B	206.0B	-5.53%	31.32%	25.24	0.47	12.55%	-43.95%
HCA	81.2B	66.7B	-5.70%	11.51%	14.85	1.22	9.59%	-4.59%
CVS	70.3B	360.9B	-24.95%	-20.81%	9.59	0.19	9.07%	78.49%
CNC	40.1B	155.5B	3.24%	9.87%	14.66	0.26	6.34%	84.42%
DVA	12.0B	12.3B	2.44%	54.71%	14.72	0.97	5.77%	58.74%
UHS	11.7B	14.3B	-2.47%	18.45%	16.34	0.82	6.59%	6.24%
MID-CAP
CHE	8.6B	2.3B	-9.43%	3.65%	30.47	3.76	5.96%	18.29%
ACHC	6.3B	3.0B	-10.75%	-1.99%	-556.53	2.1	10.92%	-104.06%
AMN	2.3B	3.8B	3.35%	-34.07%	10.77	0.6	-27.73%	-52.50%
AMEH	2.1B	1.4B	-8.29%	9.78%	34.95	1.53	21.19%	34.42%
SMALL-CAP
ADUS	1.6B	1.1B	-4.13%	19.44%	25.41	1.5	11.31%	35.83%
BKD	1.4B	3.0B	7.83%	85.28%	-7.31	0.46	6.74%	20.73%
BEAT	55.3M	-	0.47%	-0.44%	-3.78	-	-	-12.94%
AMS	19.4M	21.3M	4.44%	9.29%	36.34	0.91	8.00%	-62.25%

Augmedix, Inc. News

Latest updates

Augmedix, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	7.8%	12,680,000	11,767,000	10,780,000	9,628,000	8,751,000	7,864,000	7,333,000	6,985,000	6,577,000	5,625,000	5,173,000	4,790,000	4,543,020	4,245,000	3,725,000	3,969,961	-
Cost Of Revenue	-100.0%	-	5,937,000	5,715,000	5,242,000	4,702,000	4,274,000	4,131,000	3,872,000	3,640,000	3,092,000	2,761,000	2,665,000	2,535,913	2,368,000	2,195,000	2,590,174	-
Gross Profit	7.1%	6,245,000	5,830,000	5,065,000	4,386,000	4,049,000	3,590,000	3,202,000	3,113,000	2,937,000	2,533,000	2,412,000	2,125,000	2,007,107	1,877,000	1,530,000	1,379,787	-
Operating Expenses	3.5%	10,593,000	10,233,000	9,999,000	9,480,000	9,489,000	9,048,000	9,141,000	8,647,000	7,545,000	7,083,000	6,447,000	6,529,000	5,577,044	5,232,000	4,080,000	5,597,912	-
S&GA Expenses	0.6%	2,746,000	2,729,000	2,649,000	2,563,000	2,339,000	2,304,000	2,320,000	2,320,000	1,830,000	2,035,000	1,728,000	1,574,000	1,452,986	887,000	819,000	1,239,028	3,559,929
R&D Expenses	0.1%	2,940,000	2,936,000	2,590,000	2,710,000	2,612,000	2,608,000	2,649,000	2,280,000	1,943,000	1,810,000	1,499,000	1,426,000	1,036,955	1,009,000	985,000	1,491,091	-
EBITDA Margin	14.6%	-0.37	-0.43	-0.51	-0.64	-0.72	-0.54	-0.57	-0.62	-0.68	-	-	-	-	-	-	-	-
Interest Expenses	57.4%	524,000	333,000	386,000	281,000	427,000	-	365,000	450,000	323,000	460,000	437,000	393,000	633,208	1,458	1,342	320,785	1,365,732
Income Taxes	-127.4%	-23,000	84,000	51,000	33,000	71,000	19,000	2,000	19,000	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-4.4%	-4,515,000	-4,323,000	-4,982,000	-5,206,000	-5,528,000	-5,471,000	-7,333,000	-6,006,000	-	-	-	-	-	-	-	-	-
EBT Margin	13.4%	-0.42	-0.49	-0.57	-0.70	-0.79	-0.61	-0.66	-0.71	-0.79	-	-	-	-	-	-	-	-
Net Income	-1.9%	-4,492,000	-4,407,000	-5,033,000	-5,239,000	-5,599,000	-5,490,000	-7,335,000	-6,025,000	-5,186,000	-2,737,000	-4,715,000	-4,918,000	-3,791,000	-4,116,000	-2,959,000	-4,738,000	-18,472,788
Net Income Margin	13.7%	-0.43	-0.50	-0.58	-0.70	-0.79	-0.84	-0.80	-0.77	-0.79	-0.80	-0.94	-0.91	-0.95	-	-	-	-
Free Cashflow	20.7%	-2,166,000	-2,730,000	-7,256,000	-6,394,000	-4,978,000	-3,732,000	-4,859,000	-4,612,000	-5,470,000	-5,562,000	-2,714,000	-5,457,000	-4,320,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2	2019Q1
Assets	63.4%	67.00	41.00	44.00	33.00	34.00	37.00	41.00	46.00	52.00	19.00	23.00	25.00	28.00	25.00	22.00	19.00	16.00	-	-
Current Assets	71.8%	57.00	33.00	36.00	28.00	30.00	33.00	36.00	43.00	51.00	18.00	22.00	24.00	27.00	0.00	0.00	10*	14.00	0.00	0.00
Cash Equivalents	114.0%	46.00	22.00	25.00	21.00	21.00	26.00	30.00	37.00	42.00	11.00	17.00	19.00	23.00	3.00	5.00	6.00	12.00	0.00	0.00
Net PPE	24.6%	4.00	3.00	3.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	1.00	-	-
Liabilities	8.2%	43.00	40.00	40.00	36.00	32.00	31.00	29.00	28.00	28.00	26.00	28.00	26.00	25.00	25.00	26.00	26.00	27.00	9.00	0.00
Current Liabilities	-4.4%	24.00	25.00	21.00	17.00	19.00	16.00	13.00	14.00	14.00	11.00	11.00	10.00	16.00	0.00	0.00	0.00	13.00	0.00	0.00
Shareholder's Equity	3077.2%	23.00	1.00	4.00	-	1.00	6.00	12.00	18.00	24.00	-	-	-	3.00	-	-	-	-	-	-
Retained Earnings	-3.2%	-144	-140	-136	-131	-125	-120	-115	-107	-101	-96.28	-93.42	-88.78	-83.88	-0.11	-0.09	-0.08	-68.27	-0.05	-0.04
Additional Paid-In Capital	19.1%	169	142	141	128	128	127	126	126	125	89.00	89.00	88.00	87.00	-	-	-	3.00	-	-
Shares Outstanding	17.8%	49.00	41.00	41.00	38.00	37.00	37.00	37.00	37.00	37.00	27.00	27.00	27.00	-	-	-	-	-	-	-
Float	-	-	-	117	-	-	-	33.00	-	-	-	38.00	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	57.6%	-973	-2,293	-5,954	-6,221	-4,386	-3,531	-4,697	-4,159	-5,282	-5,457	-2,553	-5,300	-4,100	-1,747	-2,933	-5,618	-14,622	-12.29	-3.72	-7.35	-
Share Based Compensation	15.5%	736	637	565	533	720	477	491	424	393	371	239	384	177	99.00	295	97.00	-	-	-	-	-
Cashflow From Investing	-173.0%	-1,193	-437	-1,302	-173	-592	-201	-162	-453	-188	-105	-161	-157	-220	-112	-58.48	-256	-	-	-	-	-
Cashflow From Financing	131805.0%	26,381	20.00	11,884	5,085	7.00	4.00	-1,261	13.00	35,946	-3.00	62.00	1,822	23,864	-125	2,180	498	17,144	5.00	8.00	11.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AUGX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 44,855	$ 30,933
Cost of revenues	23,329	16,979
Gross profit	21,526	13,954
Operating expenses:
General and administrative	18,442	16,893
Sales and marketing	10,687	9,283
Research and development	11,176	10,149
Total operating expenses	40,305	36,325
Loss from operations	(18,779)	(22,371)
Other income (expenses):
Interest expense	(2,253)	(1,675)
Interest income	1,110	245
Loss on debt extinguishment	0	(1,097)
Change in fair value of warrant liability	(105)	0
Other	1,001	560
Total other income (expenses)	(247)	(1,967)
Loss before income taxes	(19,026)	(24,338)
Income tax expense	145	111
Net loss	(19,171)	(24,449)
Other comprehensive loss:
Foreign currency translation adjustment	(479)	(370)
Total comprehensive loss	$ (19,650)	$ (24,819)
Net loss per share of common stock, basic (in dollars per share)	$ (0.44)	$ (0.65)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.44)	$ (0.65)
Weighted average shares of common stock outstanding, basic (in shares)	43,946,263	37,418,463
Weighted average shares of common stock outstanding, diluted (in shares)	43,946,263	37,418,463

AUGX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 46,217	$ 21,251
Restricted cash	125	125
Accounts receivable, net of allowance for doubtful accounts of $110 and $102 at December 31, 2023 and 2022, respectively	8,572	6,354
Prepaid expenses and other current assets	1,909	1,820
Total current assets	56,823	29,550
Property and equipment, net	3,739	1,573
Operating lease right of use asset	5,220	1,567
Restricted cash, non-current	0	612
Deposits and other assets	930	339
Total assets	66,712	33,641
Current liabilities:
Loan payable, current portion	5,000	3,750
Accounts payable	721	1,563
Accrued expenses and other current liabilities	6,589	5,321
Deferred revenue	8,963	7,254
Operating lease liability, current portion	1,494	872
Customer deposits	851	554
Total current liabilities	23,618	19,314
Loan payable, net of current portion	15,303	11,384
Other liabilities	421	509
Operating lease liability, net of current portion	4,049	968
Total liabilities	43,391	32,175
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized; 48,613,714 and 37,442,663 shares issued and outstanding at December 31, 2023 and 2022, respectively	5	4
Additional paid-in capital	169,197	127,693
Accumulated deficit	(144,962)	(125,791)
Accumulated other comprehensive loss	(919)	(440)
Total stockholders’ equity	23,321	1,466
Total liabilities and stockholders’ equity	$ 66,712	$ 33,641

About Augmedix, Inc.

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

CEO	Mr. Emmanuel Krakaris
WEBSITE	augmedix.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1040

Augmedix, Inc. Frequently Asked Questions

What is the ticker symbol for Augmedix, Inc.? What does AUGX stand for in stocks?

AUGX is the stock ticker symbol of Augmedix, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Augmedix, Inc. (AUGX)?

As of Mon May 06 2024, market cap of Augmedix, Inc. is 132.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AUGX stock?

You can check AUGX's fair value in chart for subscribers.

What is the fair value of AUGX stock?

You can check AUGX's fair value in chart for subscribers. The fair value of Augmedix, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Augmedix, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AUGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Augmedix, Inc. a good stock to buy?

The fair value guage provides a quick view whether AUGX is over valued or under valued. Whether Augmedix, Inc. is cheap or expensive depends on the assumptions which impact Augmedix, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AUGX.

What is Augmedix, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 06 2024, AUGX's PE ratio (Price to Earnings) is -6.9 and Price to Sales (PS) ratio is 2.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUGX PE ratio will change depending on the future growth rate expectations of investors.